Glowing translucent DNA double helix — Zermatt Biotech's precision therapeutics platform

Precision Therapeutics. Redefined.

Pioneering the next generation of targeted therapies through computational biology and protein engineering.

Explore Our Platform View Pipeline

Our Platform

01

Computational Discovery

Leveraging advanced algorithms to predict and design novel protein therapeutics with high specificity.

Learn more →
02

Protein Engineering

Optimizing binding properties and stability for superior clinical efficacy and safety.

Learn more →
03

Targeted Delivery

Developing innovative modalities to ensure precise delivery to disease sites, minimizing off-target effects.

Learn more →

Our Pipeline

Drug development progression — molecular candidates evolving from discovery to clinical phases
Program
Target / Indication
Discovery Preclinical IND-Enabling Phase 1
ZMT-001 Rare Neuroinflammation
Aicardi–Goutières Syndrome
ZMT-102 Neuroinflammation
Type-I IFN-driven (indication TBD)
ZMT-205 Autoimmune
IFN-driven autoimmune (indication TBD)
View Full Pipeline

Placeholder programs — replace with Zermatt's real pipeline. See /science for the AGS-focused detailed pipeline.

Zermatt scientist analyzing molecular signaling pathways — modern biotech laboratory

Powered by Science.
Driven by Impact.

We are a team of dedicated scientists, engineers, and clinicians committed to transforming patients' lives — from mechanism to medicine.

Read Our Science